Cancer
Conditions
Keywords
lapatinib, breast cancer
Brief summary
This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior chemotherapy or anti-HER2/neu targeted therapy in the metastatic and relaps setting.
Detailed description
This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior chemotherapy or anti-HER2/neu targeted therapy in the metastatic and relaps setting. Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks. The study treatment will continue until patients experience disease progression or unacceptable toxicity. The primary objective of the study is the objective response rate (ORR, defined as CR + PR) and toxicity. Secondary objectives include DFS, duration of response.
Interventions
DRUGlapatinib and Vinorelbine
Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed adenocarcinoma of the breast. * Patients must be \> 18 years of age * Metastatic breast cancer (stage IV) at primary diagnosis or at relapse after curative intent therapy. * Laboratory confirmed HER2/neu overexpressing and/or amplified disease in the invasive component of the primary or metastatic lesion * Patients must have evidence of metastatic disease, but measurable disease is not mandatory. * The patients may have received or not prior treatment with chemotherapeutic agents including taxanes, trastuzumab or anthracycline in the adjuvant or metastatic setting is permitted. * Prior treatments with radiation therapy in the adjuvant and/or metastatic setting are permitted provided that at least 4 weeks have elapsed since the last fraction of radiation therapy and all treatment related adverse events are \< grade 1 at the time of enrollment. * Prior radiation to a solitary metastatic lesion is permitted provided that progression post radiation has been documented. * Patients must have life expectancy \> 3 months. * ECOG performance status 0, 1 or 2 (see Appendix II). * Patients must have normal organ and marrow function measured within 14 days prior to enrollment as defined Table 1. * Left ventricular ejection fraction \> 50% as demonstrated by MUGA scan/echocardiogram within 4 weeks prior to enrollment. * Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to enrollment and must use an acceptable method of contraception for the duration of the study. Female patients who are lactating should discontinue nursing prior to the first dose of investigational product and should refrain from nursing throughout the treatment period and for 14 days following the last dose of investigational product. * The patient must sign the consent form prior to enrollment. * Patients must be accessible for treatment and follow-up.
Exclusion criteria
* Patients with a history of other malignancies, except: adequately treated DCIS, adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours (non-breast) curatively treated with no evidence of disease for \> 5 years. * Patients receiving ongoing anticancer treatment or other investigational anti-cancer agents for breast cancer or patients who have used an investigational drug within 30 days or 5 half-lives (if known), whichever is longer, preceding the date of enrollment. * Patients with symptomatic CNS metastases (including leptomeningeal involvement). * Patients with only bone metastasis. * Patients with serious cardiac illness or condition including, but not limited to: history of documented congestive heart failure (CHF) or systolic dysfunction (LVEF\<50%) high risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately rate-controlled) unstable angina pectoris requiring anti-anginal medication clinically significant valvular heart disease evidence of transmural infarction on ECG inadequately controlled hypertension (systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 100 mmHg). New York Heart Association (NYHA) Class III or IV functional status (see Appendix X) * Patients who have received vinorelbine as a prior therapy in the metastatic and recurrent setting. * Patients with serious illness or medical condition which would not permit the patient to be managed according to the protocol including, but not limited to: * History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements. * Active uncontrolled infection. Serious or non-healing wound, ulcer, or bone fracture. * Patients with GI tract disease resulting in an inability to take oral medication such as but not limited to malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption (for example resection of stomach or small bowel) or uncontrolled inflammatory GI disease (e.g. Crohn's, ulcerative colitis). * Patients receiving CYP3A4 inhibitors or inducers are not eligible unless it has been \> 7 and \> 14 days, respectively since the last dose of medication before the start of protocol treatment (see Appendix IX). For amiodarone in particular, dosing is prohibited for at least 6 months prior to the start of protocol treatment. * Patients with history of allergic or hypersensitivity reactions to any study drug or their excipients or with a history of allergic reactions attributed to compounds with similar chemical composition to any of the study drugs. * Pregnant or lactation women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24 | Week 12 and Week 24 | Par. with CB are defined as those with complete response (CR), partial response (PR), or stable disease (SD) for \>=12 or 24 weeks. Per Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1, CR is defined as the disappearance of all target lesions, PR is defined as a \>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD, and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as a reference the smallest sum LD since the treatment started. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | From the start of treatment until disease progression, death, or discontinuation from the study (average of 102.7 months) | Per RECIST, Version 1.1, Progressive Disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
| Duration of Response | From the start of treatment until a complete response or partial response was reached (up to Week 90; average of 21.3 weeks) | Duration of response was measured in participants who experienced either a complete response or a partial response. Per RECIST, Version 1.1, complete response is defined as the disappearance of all target lesions, and partial response is defined as a \>=30% decrease in the sum of the longest diameter of target lesions, taking as a reference the baseline sum longest diameter. |
Countries
Turkey (Türkiye)
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 Participants received 1250 milligram (mg) tablets lapatinib once a day and vinorelbine 20 mg/meters squared (m\^2) intravenously on Day 1 and Day 8, and every 3 weeks. | 29 |
| Total | 29 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Protocol Violation | 1 |
| Overall Study | Withdrawal by Subject | 3 |
Baseline characteristics
| Characteristic | Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 |
|---|---|
| Age Continuous | 54 Years STANDARD_DEVIATION 13.2 |
| Race/Ethnicity, Customized Caucasian | 29 participants |
| Sex: Female, Male Female | 29 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 27 / 29 |
| serious Total, serious adverse events | 8 / 29 |
Outcome results
Primary
Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24
Par. with CB are defined as those with complete response (CR), partial response (PR), or stable disease (SD) for \>=12 or 24 weeks. Per Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1, CR is defined as the disappearance of all target lesions, PR is defined as a \>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD, and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as a reference the smallest sum LD since the treatment started.
Time frame: Week 12 and Week 24
Population: All participants randomized to receive at least one dose of study drug. Of the 29 participants enrolled in the study, 25 were evaluable for analysis; 4 participants withdrew from the study.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 | Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24 | Week 12, CR | 0 participants |
| Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 | Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24 | Week 12, PR | 4 participants |
| Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 | Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24 | Week 12, SD | 12 participants |
| Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 | Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24 | Week 24, CR | 0 participants |
| Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 | Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24 | Week 24, PR | 4 participants |
| Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 | Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24 | Week 24, SD | 10 participants |
Secondary
Duration of Response
Duration of response was measured in participants who experienced either a complete response or a partial response. Per RECIST, Version 1.1, complete response is defined as the disappearance of all target lesions, and partial response is defined as a \>=30% decrease in the sum of the longest diameter of target lesions, taking as a reference the baseline sum longest diameter.
Time frame: From the start of treatment until a complete response or partial response was reached (up to Week 90; average of 21.3 weeks)
Population: All participants randomized to receive at least one dose of study drug. Only those participants with a complete or partial response were evaluated.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 | Duration of Response | 4.6 months |
Secondary
Progression-free Survival
Per RECIST, Version 1.1, Progressive Disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: From the start of treatment until disease progression, death, or discontinuation from the study (average of 102.7 months)
Population: All participants randomized to receive at least one dose of study drug. Of the 29 participants enrolled in the study, 25 were evaluable for analysis; 4 participants withdrew from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Lapatinib 1250 mg and Vinorelbine 20 mg/m^2 | Progression-free Survival | 87.7 months | Standard Deviation 8.7 |